1.Effects of relaxation training on sudden deafness patients with mild-to-moderate
Weiqing ZHUANG ; Zuowei MENG ; Hong ZOU ; Suhua LIAO
Chinese Journal of Practical Nursing 2014;30(23):21-23
Objective To evaluate the effect of relaxation training on sudden deafness patients with mild or moderate grade.Methods 78 patients were divided into the observation group (38 cases) and the control group (40 cases).Besides usual care and nursing,the observation group was treated with relaxation training daily in the morning and evening.The pure tone audiometry scores before and after nursing intervention and treatment was compared between two groups.Results There was significant difference in threshold level between two groups.Conclusions Relaxation training was an effective nursing intervention for sudden deafness patients with mild-to-moderate grade.
2.Genetic analysis of unexplained neonatal encephalopathy
Jingjing XIE ; Xiaoming PENG ; Xirong GAO ; Guinan LI ; Ruiwen HUANG ; Yan ZHUANG ; Fan ZHANG ; Weiqing HUANG ; Junshuai LI ; Rong ZHANG
Chinese Journal of Perinatal Medicine 2023;26(2):127-133
Objective:To explore the potential genetic causes of unexplained neonatal encephalopathy.Methods:This retrospective study enrolled 113 infants diagnosed with unexplained neonatal encephalopathy and underwent genetic testing in the Children's Hospital of Hunan Province from January 2019 to May 2021. Perinatal data, clinical manifestations, electroencephalograph, brain MRI findings, genetic information, and prognosis of those patients were analyzed. T-test or Chi-square test were used for data analysis. Results:Of the 113 infants enrolled, 74 (65.5%) were males. The gestational age at birth was (38.6±1.5) weeks, and the birth weight was (2 957±561) g. The most common clinical manifestation was the disturbance of consciousness (83/113, 73.5%), followed by seizures (39/113, 34.5%). There were 38.2% (34/89) of the patients with abnormal brain MRI, and 80.4% (74/92) presented abnormal electroencephalography. Among the 113 infants, 60 (53.1%) had genetic abnormalities, including 48 with single nucleotide variations, eight with copy number variations, and four with chromosome abnormalities. Single nucleotide variations in the 48 patients were classified into syndromic ( n=18, 37.5%), metabolic ( n=16, 33.3%), epileptic ( n=11, 22.9%) and mitochondrial-related genes ( n=3, 6.3%), of which 14 were not included in any database. Among the 103 cases which were successfully followed up until December 31, 2021, 75 (72.8%) had a poor prognosis, including 52 (50.5%) death cases and 23 (22.3%) cases of development retardation. Birth weight and the incidence of seizures in the poor prognosis group were both lower than those in the non-poor prognosis group [(2 876±536) vs (3 254±554) g, t=3.15; 29.3% (22/75) vs 53.6% (15/28), χ2=5.20; both P<0.05], while the incidence of disturbance of consciousness was higher [80.0% (60/75) vs 53.6% (15/28), χ2=7.19, P<0.05]. The proportion of infants with genetic abnormalities in the poor prognosis group was higher than that in the non-poor prognosis group, but the difference was not statistically significant [53.3% (40/75) vs 46.4% (13/28), χ2=0.39, P=0.533]. Conclusions:Genetic abnormality is one of the leading causes of unexplained neonatal encephalopathy. Nucleotide variation is the most common genetic type. Syndromic, metabolic, and epileptic variants are frequently detected in these patients.
3.Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2.
Haiyan YAN ; Jing SUN ; Kun WANG ; Huiqiang WANG ; Shuo WU ; Linlin BAO ; Weiqing HE ; Dong WANG ; Airu ZHU ; Tian ZHANG ; Rongmei GAO ; Biao DONG ; Jianrui LI ; Lu YANG ; Ming ZHONG ; Qi LV ; Feifei QIN ; Zhen ZHUANG ; Xiaofang HUANG ; Xinyi YANG ; Yuhuan LI ; Yongsheng CHE ; Jiandong JIANG
Acta Pharmaceutica Sinica B 2021;11(9):2850-2858
COVID-19 pandemic caused by SARS-CoV-2 infection severely threatens global health and economic development. No effective antiviral drug is currently available to treat COVID-19 and any other human coronavirus infections. We report herein that a macrolide antibiotic, carrimycin, potently inhibited the cytopathic effects (CPE) and reduced the levels of viral protein and RNA in multiple cell types infected by human coronavirus 229E, OC43, and SARS-CoV-2. Time-of-addition and pseudotype virus infection studies indicated that carrimycin inhibited one or multiple post-entry replication events of human coronavirus infection. In support of this notion, metabolic labelling studies showed that carrimycin significantly inhibited the synthesis of viral RNA. Our studies thus strongly suggest that carrimycin is an antiviral agent against a broad-spectrum of human coronaviruses and its therapeutic efficacy to COVID-19 is currently under clinical investigation.